Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Non Operating Income: 2022-2025

Historic Non Operating Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $1.3 million.

  • Taysha Gene Therapies' Non Operating Income rose 245.19% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 96.78%. This contributed to the annual value of $2.2 million for FY2024, which is 105.52% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Non Operating Income stood at $1.3 million, which was up 644.73% from -$237,000 recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Non Operating Income peaked at $64.0 million during Q4 2023, and registered a low of -$100.8 million during Q3 2023.
  • Moreover, its 3-year median value for Non Operating Income was $269,000 (2024), whereas its average is -$3.3 million.
  • The largest annual percentage gain for Taysha Gene Therapies' Non Operating Income in the last 5 years was 5,854.23% (2023), contrasted with its biggest fall of 9,324.02% (2023).
  • Over the past 4 years, Taysha Gene Therapies' Non Operating Income (Quarterly) stood at -$1.1 million in 2022, then skyrocketed by 5,854.23% to $64.0 million in 2023, then plummeted by 98.21% to $1.1 million in 2024, then spiked by 245.19% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$237,000 for Q2 2025, and -$108,000 during Q1 2025.